Literature DB >> 31954515

Brain-specific chemokine FAM19A5 induces hypothalamic inflammation.

Dasol Kang1, Han Rae Kim2, Kwang Kon Kim1, Dong Hee Kim1, Bora Jeong1, Sungho Jin1, Jeong Woo Park1, Jae Young Seong3, Byung Ju Lee4.   

Abstract

The cytokine-like protein FAM19A5 is highly expressed in the brain, but little is known about its functions there. Here, we found that FAM19A5 was expressed in mouse hypothalamic cells expressing proopiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related peptide (AgRP), and in the microglia. Tumor necrosis factor-α (TNF-α), which induces inflammatory sickness responses, greatly increased hypothalamic expression of FAM19A5. Knockdown of FAM19A5 expression resulted in decreased TNF-α-induced anorexia, body weight loss and TNF-α-induced expression of inflammatory factors. In contrast, intracerebroventricular administration of FAM19A5 induced anorexia, body weight loss and hyperthermia, together with increased expression of inflammatory factors. FAM19A5 injection also induced increases in c-fos activation and POMC mRNA level in hypothalamic POMC neurons. Together, these results suggest that FAM19A5 plays an important role in hypothalamic inflammatory responses.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anorexia; Hyperthermia; Hypothalamic inflammation; Proinflammatory cytokines; Sickness responses; Tumor necrosis factor-α (TNF-α)

Year:  2020        PMID: 31954515     DOI: 10.1016/j.bbrc.2019.12.119

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Molecular Structure, Expression and Role of TAFA4 and its Receptor FPR1 in the Spinal Cord.

Authors:  Sipin Zhu; Xiaoyong Hu; Samuel Bennett; Yuliang Mai; Jiake Xu
Journal:  Front Cell Dev Biol       Date:  2022-05-31

2.  Development and Validation of a Plasma FAM19A5 and MRI-Based Radiomics Model for Prediction of Parkinson's Disease and Parkinson's Disease With Depression.

Authors:  Xue-Ning Li; Da-Peng Hao; Mei-Jie Qu; Meng Zhang; An-Bang Ma; Xu-Dong Pan; Ai-Jun Ma
Journal:  Front Neurosci       Date:  2021-12-17       Impact factor: 4.677

3.  Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.

Authors:  Mahmoud S Abdallah; Ahmed N Ramadan; Hend Omara-Reda; Noha O Mansour; Mohamed A Elsokary; Hozaifa K Elsawah; Shimaa Abdelsattar Zaki; Hend E Abo Mansour; Esraa M Mosalam
Journal:  CNS Neurosci Ther       Date:  2021-09-21       Impact factor: 5.243

4.  Increased level of FAM19A5 is associated with cerebral small vessel disease and leads to a better outcome.

Authors:  Zhongnan Hao; Shaonan Yang; Ruihua Yin; Jin Wei; Yuan Wang; Xudong Pan; Aijun Ma
Journal:  PeerJ       Date:  2022-03-08       Impact factor: 2.984

5.  Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia.

Authors:  Juan Li; Shoulin Li; Yihong Song; Wei Zhou; Xiaohao Zhu; Suo Xu; Yihong Ma; Chunlin Zhu
Journal:  Dis Markers       Date:  2020-08-01       Impact factor: 3.434

6.  FAM19A5l Affects Mustard Oil-Induced Peripheral Nociception in Zebrafish.

Authors:  Inyoung Jeong; Seongsik Yun; Anu Shahapal; Eun Bee Cho; Sun Wook Hwang; Jae Young Seong; Hae-Chul Park
Journal:  Mol Neurobiol       Date:  2021-06-26       Impact factor: 5.590

7.  Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease.

Authors:  Hossein Poustchi; Ahmad Reza Bandegi; Fatemeh Ali Yari; Parisa Shabani; Sara Karami; Negar Sarmadi
Journal:  BMC Endocr Disord       Date:  2021-08-03       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.